Nifedipine

Generic Name: Nifedipine

Brand Names: Adalat, Afeditab CR, Nifediac, Nifedical, Procardia

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₈N_₂O_₆

CAS Number: 21829-25-4

Unique Ingredient Identifier: I9ZF7L6G2L

Background: Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to nicardipine. Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972. Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action. The most popular of the third generation dihydropyridines is amlodipine.

Nifedipine was granted FDA approval on 31 December 1981.

Indication: Nifedipine capsules are indicated to treat vasospastic angina and chronic stable angina. Extended release tablets are indicated to treat vasospastic angina, chronic stable angina, and hypertension.

Associated Conditions: Achalasia, Chronic Stable Angina Pectoris, Fissure;Anal, Hypertension, Hypertensive Emergency, Premature Labour, Proctalgia, Pulmonary Edemas, Pulmonary Hypertension (PH), Raynaud's Phenomenon, Ureteral Calculus, Vasospastic Angina

Clinical Trials

Comparison of Nifedipine Versus Indomethacin for Acute Preterm Labor

Not Applicable

Completed

Conditions: Obstetric Labor, Premature

Interventions: Drug: Nifedipine
Drug: Indomethacin

First Posted Date: 2017-04-26

Last Posted Date: 2021-11-05

Lead Sponsor: University of California, Irvine

Target Recruit Count: 36

Registration Number: NCT03129945

Locations: 🇺🇸
University of California, Davis, Sacramento, California, United States
🇺🇸
University of California, Irvine, Orange, California, United States
🇺🇸
University of California, Los Angeles, Los Angeles, California, United States

and more 2 locations

Use of Impedance Cardiography to Decrease the Risk of Pre-eclampsia in Obese Patients

Early Phase 1

Conditions: Obesity, Morbid
Preeclampsia

Interventions: Drug: Labetalol Hydrochloride 200 mg
Drug: NIFEdipine 60 mg
Drug: Atenolol 25 mg

First Posted Date: 2017-04-10

Last Posted Date: 2019-02-22

Lead Sponsor: University of Tennessee Graduate School of Medicine

Target Recruit Count: 400

Registration Number: NCT03105661

Locations: 🇺🇸
University of Tennessee Medical Center, Knoxville, Tennessee, United States

Drug Interaction With Proton Pump Inhibitors for Nifedipine ER Tablets

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Nifedipine 60 MG Extended Release Oral Tablet
Device: SmartPill (TM)
Drug: omeprazole/sodium bicarbonate

First Posted Date: 2017-04-04

Last Posted Date: 2019-08-16

Lead Sponsor: Food and Drug Administration (FDA)

Target Recruit Count: 64

Registration Number: NCT03100838

Locations: 🇺🇸
BioPharma Services Inc., Columbia, Missouri, United States

Comparative Study Between Nifedipine and Ritodrine as Maintenance Tocolytic Therapy in Preterm Labor

Phase 4

Completed

Conditions: Preterm Birth

Interventions: Drug: Nifedipine 20 Mg
Drug: Ritodrine Oral Tablet

First Posted Date: 2017-02-02

Last Posted Date: 2019-09-24

Lead Sponsor: Cairo University

Target Recruit Count: 200

Registration Number: NCT03040752

Locations: 🇪🇬
Kasr Alainy medical school, Cairo, Egypt

Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud

Early Phase 1

Completed

Conditions: Raynaud Disease
System; Sclerosis
Raynaud Phenomenon Due to Trauma
Dermatomyositis
Lupus Erythematosus, Systemic
Ultrasound Therapy; Complications